Context Therapeutics Inc. (NASDAQ:CNTX) Stock Has Consensus Target Price of $6.17 According to Brokerages

Context Therapeutics Inc. (NASDAQ:CNTX) has received an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and eight have given a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $6.17.

Several analysts have recently issued reports on the stock. Weiss Ratings cut shares of Context Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, September 3rd. Citigroup restated an “outperform” rating on shares of Context Therapeutics in a report on Thursday, August 6th. Maxim Group decreased their target price on Context Therapeutics from $8.00 to $4.00 and set a “buy” rating for the company in a report on Tuesday, June 16th. Lifesci Capital lowered shares of Context Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, August 6th. Finally, Wall Street Zen cut shares of Context Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Monday, July 20th.

Context Therapeutics Price Performance

Shares of CNTX stock opened at $0.35 on Friday. The firm has a market cap of $31.76 million, a P/E ratio of -0.72 and a beta of 1.69. Context Therapeutics has a 1-year low of $0.34 and a 1-year high of $3.62. The firm’s 50-day simple moving average is $0.47 and its 200-day simple moving average is $1.45.

Context Therapeutics (NASDAQ:CNTX) last released its earnings results on Wednesday, August 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.06). Analysts expect that Context Therapeutics will post -0.45 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Context Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in CNTX. Octagon Capital Advisors LP acquired a new stake in Context Therapeutics in the 1st quarter valued at $13,755,000. Blue Owl Capital Holdings LP acquired a new position in shares of Context Therapeutics during the second quarter worth about $1,625,000. BlackRock Inc. acquired a new position in shares of Context Therapeutics during the second quarter worth about $3,417,000. Deutsche Bank AG purchased a new stake in shares of Context Therapeutics in the second quarter worth about $50,000. Finally, Two Sigma Securities LLC boosted its position in shares of Context Therapeutics by 388.7% in the second quarter. Two Sigma Securities LLC now owns 61,444 shares of the company’s stock worth $34,000 after buying an additional 48,871 shares during the period. Institutional investors and hedge funds own 14.03% of the company’s stock.

About Context Therapeutics

Context Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing targeted and immune-based treatments for solid tumors, with an emphasis on cancers that have limited treatment options. The company is headquartered in Philadelphia and conducts development activities through collaborations and clinical research networks.

Its lead investigational program is CTIM-76, a bispecific antibody designed to recognize Claudin 6 (CLDN6) on tumor cells and CD3 on T cells.